Abstract: Targeted anti-cancer agents have now become one of the cutting-edge hotspots in the field of cancer therapy and have brought considerable therapeutic benefits to many patients. Ocular toxicity is one of the adverse events that may not be aware enough, affecting patients' living quality and treatment process. Common ocular toxicities include conjunctivitis, keratitis, dry eye, retinal hemorrhage, retinal detachment, etc. Ophthalmologists should fully acknowledge the feature of ocular toxicity caused by theses novel therapeutics, maximize the treating benefits to patients and improve life quality. (Int Rev Ophthalmol, 2025, 49:  115-118)

Key words: targeted anti-cancer agents, ocular toxicity